Skip to main content
Delfa

← Trials/Trial dossier/NCT00203359

CompletedPhase 1

TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

Etanercept for Alzheimer's-Type Memory Loss Pilot Study

Asset

Etanercept

Listed sites

1

Recruiting sites

-

Enrollment

15

Study population

Alzheimer’s disease

Key I/E criterion

•Age ≥0

Primary endpoints

•ADAS-Cog•SIB•Mini-Mental State Examination (MMSE)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID10005
NCT IDNCT00203359

Timeline

Milestones

Study start2004-09 (month precision)
Study first posted2005-09-20estimated
Study completion2006-04 (month precision)
Last update posted2006-04-24estimated

Assets

Drug assets

Etanercept

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age0 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•NINCDS-ADRDA Criteria for Alzheimer's disease
•CT or MRI consistent with AD

Exclusion criteria

•active infection
•CHF
•demyelinating disease
•uncontrolled diabetes mellitus
•vascular dementia
•clinically significant neurologic disease other than AD
•Hachinski >4
•history of lymphoma
•TBC
•wbc<2500
•platelets<100,000
•HCT<30
•pregnancy
•premenopausal, fertile not on acceptable birth control
•change in neuroactive medication within 4 weeks of study initiation

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
3
Other (unclassified)
2

Global cognition

3 endpoints
Primary/protocol endpoint

ADAS-Cog

ADAS-Cog

descriptive

Primary/protocol endpoint

SIB

descriptive

Primary/protocol endpoint

MMSE

Mini-Mental State Examination (MMSE)

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Category fluency

categorical status, descriptive

Secondary/protocol endpoint/low confidence

other neuropsychological tests

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.